PRODUCT INFORMATION

EPZ5676

Item No. 16175

CAS Registry No.:	1380288-87-8
Formal Name:	5′-deoxy-5′-[[cis-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methylethyl)amino]-adenosine
MF:	$C_{30}H_{42}N_8O_3$
FW:	562.7
Purity:	≥98%
UV/Vis.:	λ_{max}: 255 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

EPZ5676 is supplied as a crystalline solid. A stock solution may be made by dissolving the EPZ5676 in the solvent of choice, which should be purged with an inert gas. EPZ5676 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of EPZ5676 in ethanol and DMF is approximately 30 mg/ml and approximately 25 mg/ml in DMSO.

EPZ5676 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, EPZ5676 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. EPZ5676 has a solubility of approximately 0.1 mg/ml in a 1:8 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DOT1L is a non-SET domain containing methyltransferase whose function is important for the transcriptional activation of certain genes, DNA damage repair, and cell cycle regulation. DOT1L is known to play an essential role in MLL-rearranged leukemias, and thus has emerged as a drug target for these leukemias.[1,2] EPZ5676 is a highly potent aminonucleoside inhibitor of DOT1L histone methyltransferase activity (K_i = 80 pM) that demonstrates 37,000-fold selectivity over other methyltransferases.[3,4] In various human leukemia cell lines, EPZ5676 has been shown to inhibit the methylation of lysine 79 on histone 3 (IC_{50}s = 3-5 nM), decreasing MLL-fusion target gene expression (IC_{50}s = 53-67 nM).[3] It can selectively inhibit the proliferation of acute leukemia cell lines bearing MLL translocations (IC_{50}s range from 3.5 nM - 1.3 µM).[3] Continuous intravenous infusion of EPZ5676 at a dose of 35 mg/kg has been reported to cause complete and sustained tumor regression in a rat xenograft model of MLL-rearranged leukemia.[3]

References

1. Nguyen, A.T., He, J., Taranova, O., *et al.* Essential role of DOT1L in maintaining normal adult hematopoiesis. *Cell Res.* **21(9)**, 1370-1373 (2011).
2. Bernt, K.M. and Armstrong, S.A. A role for DOT1L in MLL-rearranged leukemias. *Epigenomics* **3(6)**, 667-670 (2011).
3. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., *et al.* Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. *Blood* **122(6)**, 1017-1025 (2013).
4. Basavapathruni, A., Olhava, E.J., Daigle, S.R., *et al.* Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. *Biopharm. Drug Dispos.* **35(4)**, 237-252 (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM